© 2013 Informa UK, Ltd. This provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. DISCLAIMER: The ideas and opinions expressed in the journal’s Just Accepted articles do not necessarily reflect those of Informa Healthcare (the Publisher), the Editors or the journal. The Publisher does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of the material contained in these articles. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosages, the method and duration of administration, and contraindications. It is the responsibility of the treating physician or other health care professional, relying on his or her independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Just Accepted articles have undergone full scientific review but none of the additional editorial preparation, such as copyediting, typesetting, and proofreading, as have articles published in the traditional manner. There may, therefore, be errors in Just Accepted articles that will be corrected in the final print and final online version of the article. Any use of the Just Accepted articles is subject to the express understanding that the papers have not yet gone through the full quality control process prior to publication. Just Accepted by Leukemia & Lymphoma Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinico-pathological characteristics and prognostic factors Daan Dierickx, Thomas Tousseyn , Xavier Sagaert, Steffen Fieuws, Iwona Wlodarska, Julie Morscio, Lieselot Brepoels, Dirk Kuypers, Johan Vanhaecke, Frederik Nevens, Geert Verleden, Rita Van Damme-Lombaerts, Marleen Renard, Jacques Pirenne, Christiane De Wolf-Peeters and Gregor Verhoef doi:10.3109/10428194.2013.780655 Abstract Hematopoietic stem cell and solid organ transplant recipients diagnosed with biopsy-confirmed posttransplant lymphoproliferative disorder (PTLD) at our institution from 1989 to 2010 were identified. Patient-, transplantation- and disease-related characteristics, prognostic factors and outcome were collected and analyzed. One hundred-forty biopsy-proven PTLD cases were included. Overall incidence in the transplant population was 2.12% with heart transplant recipients carrying the highest risk. Most PTLDs were monomorphic (83.6%) with diffuse large B cell lymphoma being the most frequent subtype. The majority of cases (70.7%) occurred > 1 year posttransplantation, whereas 66% were Epstein Barr virus positive. Following initial therapy overall response rate was 68.5%. Three-year relapse-free and overall survival were 59% and 49%, respectively. At last follow-up 44% of the patients were alive. Multivariable analysis identified several classical lymphoma-specific poor prognostic factors for the different outcome measures. The value of the International Prognostic Index was confirmed in our analysis. Leuk Lymphoma Downloaded from informahealthcare.com by K U Leuven on 03/01/13 For personal use only.